Project details


Changes in PSMA expression on 18F-PSMA-1107 PSMA PET/CT to systemic treatment with anti-androgens

PSMA PET/CT prostate cancer

drs. M. van Kruchten
Dr. W. Noordzij

Type of project:
Pilot project (year 2 or 3)

Nature of the research:
retrospective cohort study (creating database, perform analysis)

Fields of study:
oncology nuclear medicine

Background / introduction
Prostate cancer is one of the most frequent malignancies in men worldwide. In >80% of all prostate cancer cells, there is overexpression of prostate specific membrane antigen (PSMA), which is a type-II transmembrane glycoprotein, and provides new ways of targeted molecular imaging (PSMA PET/CT). Currently, these PSMA PET/CT scans are made in different stages of the disease, including for primary staging and in case of biochemical recurrence, but also for determination of respons to treatment.
The expression of PSMA, however, varies from patient to patient and even between different metastases, which may impact the outcome of any treatment. As of yet it is unclear if a decrease in PSMA expression corresponds to better outcome of the different systemtic treatment options.
Research question / problem definition
The purpose of this study will be to find a relation between the decrease of PSMA expression, and the clinical outcome to systemic treatment, in patients with metastasized prostate cancer.
Setting up a database for these PSMA PET/CT scan, including clinical features and outcome measures. Analyse according to the research question.
Cancers (Basel) 2022;14:1696.
doi: 10.3390/cancers14071696.
back to toptop